Image

    Safety And Efficacy Of Oral Administered Cepharanthine In Non-Hospitalized, Asymptomatic Or Mild COVID-19 Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

    January 2025 in “ Scientific Reports ”
    Jianyi Wei, Shupeng Liu, Yuexiang Bian … Hai Li
    Studysummary This study found that treating asymptomatic or mild COVID-19 with cepharanthine did not significantly reduce the time to a negative test result, though 60 mg/day showed a non-significant trend needing further validation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on nature.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2 Cell Research · 2021
    2. Roles of Existing Drugs and Drug Targets for COVID-19 Management Metabolism Open · 2021
    3. Structural Insights Into SARS-CoV-2 Spike Protein and Its Natural Mutants Found in Mexican Population Scientific Reports · 2021
    4. Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19 Pharmacological Reports · 2020
    5. Cepharanthine: An Update of Its Mode of Action, Pharmacological Properties, and Medical Applications Phytomedicine · 2019